Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Kim, S. Kamel‐Reid, Hong Chang, R. Sutherland, C. Jung, Hyeoung-Joon Kim, Je-Jung Lee, J. Lipton (2009)Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
M. Schrappe, M. Aricò, J. Harbott, A. Biondi, M. Zimmermann, V. Conter, A. Reiter, M. Valsecchi, H. Gadner, G. Basso, C. Bartram, F. Lampert, H. Riehm, G. Masera (1998)Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
Blood, 92 8
B. Druker, F. Guilhot, S. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. Deininger, R. Silver, J. Goldman, R. Stone, F. Cervantes, A. Hochhaus, B. Powell, J. Gabrilove, P. Rousselot, J. Reiffers, J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. Nielsen, J. Radich, B. Simonsson, K. Taylor, M. Baccarani, Charlene So, L. Letvak, R. Larson (2006)Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
The New England journal of medicine, 355 23
A. Quintás-Cardama, Xin Han, H. Kantarjian, J. Cortes (2009)Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Blood, 114 2
O. Ottmann, B. Wassmann (2005)Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hematology. American Society of Hematology. Education Program
M. Vignetti, P. Fazi, G. Cimino, G. Martinelli, F. Raimondo, F. Ferrara, G. Meloni, A. Ambrosetti, G. Quarta, L. Pagano, G. Rege‐Cambrin, L. Elia, R. Bertieri, L. Annino, R. Foà, M. Baccarani, F. Mandelli (2007)Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged
M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, Tohru Kobayashi, Y. Ueda, M. Takeuchi, S. Miyawaki, A. Maruta, N. Emi, Y. Miyazaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno (2006)High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 3
R. Ohno, R. Ohno, N. Asou, N. Asou, K. Ohnishi, K. Ohnishi (2003)Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate
J. Ribera, A. Oriol, Marcos González, B. Vidriales, S. Brunet, J. Esteve, E. Potro, C. Rivas, M. Moreno, M. Tormo, V. Martín-Reina, J. Sarrá, R. Parody, J. Oteyza, E. Bureo, M. Bernal (2010)Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
S. Branford, Z. Rudzki, Sonya Walsh, I. Parkinson, A. Grigg, J. Szer, K. Taylor, R. Herrmann, J. Seymour, C. Arthur, D. Joske, K. Lynch, T. Hughes (2003)Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Blood, 102 1
Kelsea Caruso, Michele Kanter (2018)Re: Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment
International Journal of Hematology, 107
D. Thomas, S. Faderl, J. Cortes, S. O'brien, F. Giles, S. Kornblau, G. Garcia-Manero, M. Keating, M. Andreeff, S. Jeha, M. Beran, S. Verstovsek, S. Pierce, L. Letvak, A. Salvado, R. Champlin, M. Talpaz, H. Kantarjian (2004)Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood, 103 12
M Vignetti, P Fazi, G Cimino (2007)Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol
S. Mustjoki, M. Ekblom, T. Arstila, I. Dybedal, PK Burnette, Felix Garzon, T. Gedde-Dahl, Sari Hernesniemi, H. Hjorth-Hansen, M. Hoglund, V. Juvonen, V. Kairisto, P. Kovanen, A. Kreutzman, T. Laurinolli, J. Liesveld, R. Paquette, J. Pinilla, A. Rauhala, N. Shah, B. Simonsson, M. Sinisalo, J. Steegmann, L. Stenke, J. Vakkila, K. Porkka (2008)Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
M. Tanimoto, S. Miyawaki, T. Ino, T. Kyo, H. Sakamaki, T. Naoe, A. Hiraoka, N. Asou, T. Ohshima, K. Tsubaki, K. Kuriyama, T. Ueda, S. Minamil, K. Okabe, H. Saito, H. Murakami, M. Hirano, H. Dohy, Y. Onozawa, H. Suzuki, R. Ohno (1998)Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG).
International journal of hematology, 68 4
N. Woerden, R. Pieters, D. Hoelzer, R. Slater, M. Boer, A. Loonen, J. Harbott, G. Janka-Schaub, W. Ludwig, G. Ossenkoppele, E. Wering, A. Veerman (2002)In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Medical and pediatric oncology, 38 6
T. O'hare, C. Eide, M. Deininger (2007)Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
Blood, 110 7
T Ueda, S Miyawaki, N Asou (1998)Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group
Int J Hematol, 68
T. Hongo, Shuichi Okada, Noriko Inoue, Sayuri Yamada, S. Yajima, C. Watanabe, Y. Fujii, Y. Horikoshi (2002)Two Groups of Philadelphia Chromosome—Positive Childhood Acute Lymphoblastic Leukemia Classified by Pretreatment Multidrug Sensitivity or Resistance in In Vitro Testing
International Journal of Hematology, 76
R. Ohno (2006)Treatment of chronic myeloid leukemia with imatinib mesylate
International Journal of Clinical Oncology, 11
B. Wassmann, H. Pfeifer, N. Goekbuget, D. Beelen, J. Beck, M. Stelljes, M. Bornhäuser, Albrecht Reichle, J. Perz, R. Haas, Arnold Ganser, M. Schmid, Lothar Kanz, Georg Lenz, M. Kaufmann, A. Binckebanck, P. Brück, R. Reutzel, H. Gschaidmeier, Stefan Schwartz, D. Hoelzer, O. Ottmann (2006)Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood, 108 5
M. Yanada, R. Ohno, T. Naoe (2009)Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
International Journal of Hematology, 89
H. Pfeifer, B. Wassmann, A. Pavlova, L. Wunderle, J. Oldenburg, A. Binckebanck, T. Lange, A. Hochhaus, S. Wystub, P. Brück, D. Hoelzer, O. Ottmann (2007)Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood, 110 2
G. Riva, M. Luppi, P. Barozzi, C. Quadrelli, S. Basso, D. Vallerini, E. Zanetti, M. Morselli, F. Forghieri, M. Maccaferri, F. Volzone, C. Giovane, R. D'amico, F. Locatelli, G. Torelli, P. Comoli, L. Potenza (2010)Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment.
Blood, 115 8
M. Lilly, O. Ottmann, N. Shah, R. Larson, J. Reiffers, G. Ehninger, M. Müller, A. Charbonnier, E. Bullorsky, H. Dombret, Mary Bradley-Garelik, Chao Zhu, G. Martinelli (2010)Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
American Journal of Hematology, 85
A. Quintás-Cardama, H. Kantarjian, F. Ravandi, S. O'brien, D. Thomas, G. Vidal-Senmache, W. Wierda, S. Kornblau, J. Cortes (2009)Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
K. Schultz, W. Bowman, A. Aledo, W. Slayton, H. Sather, M. Devidas, Chenguang Wang, S. Davies, P. Gaynon, M. Trigg, R. Rutledge, Laura Burden, D. Jorstad, A. Carroll, N. Heerema, N. Winick, M. Borowitz, S. Hunger, W. Carroll, B. Camitta (2009)Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 31
Joseph Roberts, Andrea Lengi, Stephanie Brown, Min Chen, Yong-Jie Zhou, John 'shea, Rebecca Buckley (2002)Clinical Observations, Interventions, and Therapeutic Trials
M. Aricò, M. Valsecchi, B. Camitta, M. Schrappe, J. Chessells, A. Baruchel, P. Gaynon, L. Silverman, G. Janka-Schaub, W. Kamps, Pui Ch, G. Masera (2000)Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.
The New England journal of medicine, 342 14
Seok Lee, Yoo-Jin Kim, N. Chung, Jihyang Lim, Dong‐Gun Lee, Hee‐Je Kim, C. Min, Jong-Wook Lee, W. Min, Chun‐Choo Kim (2009)The extent of minimal residual disease reduction after the first 4‐week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia
M. Towatari, M. Yanada, N. Usui, J. Takeuchi, I. Sugiura, M. Takeuchi, F. Yagasaki, Y. Kawai, S. Miyawaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno (2004)Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Blood, 104 12
T. Lugo, A. Pendergast, A. Muller, O. Witte (1990)Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Science, 247 4946
R Ohno (2006)Japan Adult Leukemia Study Group: Treatment of Philadelphia chromosome?positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy
Curr Hematol Malig Rep, 1
A. Labarthe, P. Rousselot, F. Huguet-Rigal, E. Delabesse, F. Witz, S. Maury, D. Réa, J. Cayuela, M. Vekemans, O. Reman, A. Buzyn, A. Pigneux, M. Escoffre, Y. Chalandon, E. Macintyre, V. Lheritier, J. Vernant, X. Thomas, N. Ifrah, H. Dombret (2007)Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome – positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study
R. Ohno (2008)Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Current Oncology Reports, 10
Y. Kano, M. Akutsu, S. Tsunoda, Hiroyuki Mano, Y. Sato, Y. Honma, Y. Furukawa (2001)In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Blood, 97 7
K. Porkka, Perttu Koskenvesa, T. Lundán, J. Rimpiläinen, S. Mustjoki, Richard Smykla, R. Wild, R. Luo, M. Arnán, B. Brethon, L. Eccersley, H. Hjorth-Hansen, M. Höglund, H. Klamová, H. Knutsen, S. Parikh, E. Raffoux, F. Gruber, F. Brito-Babapulle, H. Dombret, Rafael Duarte, E. Elonen, R. Paquette, C. Zwaan, Frank Lee (2008)Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Blood, 112 4
J. Thiesing, Sayuri Ohno-Jones, K. Kolibaba, B. Druker (2000)Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Blood, 96 9
OG Ottmann, BJ Druker, CL Sawyers (2002)A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome?positive acute lymphoid leukemias
R. Ohno, T. Group (2006)Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy
Current Hematologic Malignancy Reports, 1
M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, K. Nishii, Y. Ueda, M. Takeuchi, S. Miyawaki, A. Maruta, H. Narimatsu, Y. Miyazaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno (2008)Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy
A. Goldstone, H. Prentice, J. Durrant, I. Franklin, G. Harrison, S. Richards, H. Lazarus, P. Wiernik, M. Tallman, J. Rowe (2001)Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993)
M. Yanada, I. Sugiura, J. Takeuchi, H. Akiyama, A. Maruta, Y. Ueda, N. Usui, F. Yagasaki, T. Yujiri, M. Takeuchi, K. Nishii, Y. Kimura, S. Miyawaki, H. Narimatsu, Y. Miyazaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno (2008)Prospective monitoring of BCR‐ABL1 transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapy
British Journal of Haematology, 143
F. Ravandi, H. Kantarjian, D. Thomas, S. Faderl, Dan Jones, C. Koller, S. Dara, Rebecca Garris, P. Kebriaei, R. Champlin, G. Borthakur, W. Wierda, J. Burger, J. Cortes, S. O'brien (2009)Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).
C. Pui, W. Evans (2006)Treatment of acute lymphoblastic leukemia.
The New England journal of medicine, 354 2
B. Wassmann, H. Pfeifer, M. Stadler, Martin Bornhaüser, G. Bug, U. Scheuring, P. Brück, M. Stelljes, R. Schwerdtfeger, N. Basara, J. Perz, D. Bunjes, G. Ledderose, R. Mahlberg, A. Binckebanck, H. Gschaidmeier, D. Hoelzer, O. Ottmann (2005)Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood, 106 2
Yiguo Hu, Yuhua Liu, Shawn Pelletier, E. Buchdunger, M. Warmuth, D. Fabbro, M. Hallek, R. Etten, Shaoguang Li (2004)Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
Nature Genetics, 36
T. O'hare, D. Walters, E. Stoffregen, Taiping Jia, P. Manley, J. Mestan, S. Cowan-Jacob, F. Lee, M. Heinrich, M. Deininger, B. Druker (2005)In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Cancer research, 65 11
H. Dombret, J. Gabert, J. Boiron, F. Rigal-huguet, D. Blaise, X. Thomas, A. Delannoy, A. Buzyn, C. Bilhou-Nabera, J. Cayuela, P. Fenaux, J. Bourhis, N. Fegueux, C. Charrin, C. Boucheix, V. Lheritier, H. Esperou, E. Macintyre, J. Vernant, D. Fiére (2002)Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.
Blood, 100 7
D. Thomas (2007)Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.
Hematology. American Society of Hematology. Education Program
O. Ottmann, R. Larson, H. Kantarjian, P. Coutre, M. Baccarani, A. Haque, N. Gallagher, F. Giles (2007)Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.
O. Ottmann, H. Dombret, G. Martinelli, B. Simonsson, F. Guilhot, R. Larson, G. Rege‐Cambrin, J. Radich, A. Hochhaus, A. Apanovitch, A. Gollerkeri, S. Coutre (2007)Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Blood, 110 7
A. Delannoy, E. Delabesse, V. Lheritier, S. Castaigne, F. Rigal-huguet, E. Raffoux, F. Garban, O. Legrand, S. Bologna, V. Dubruille, P. Turlure, O. Reman, M. Delain, F. Isnard, D. Coso, P. Raby, A. Buzyn, S. Caillères, S. Darré, C. Fohrer, A. Sonet, C. Bilhou-Nabera, M. Béné, H. Dombret, P. Berthaud, X. Thomas, for Leukemia (2006)Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
O. Ottmann, B. Wassmann, H. Pfeifer, Aristoteles Giagounidis, M. Stelljes, U. Dührsen, M. Schmalzing, L. Wunderle, A. Binckebanck, D. Hoelzer (2007)Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL)
H. Kantarjian, D. Thomas, S. O'brien, J. Cortes, F. Giles, S. Jeha, C. Bueso-Ramos, S. Pierce, J. Shan, C. Koller, M. Beran, M. Keating, E. Freireich (2004)Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia
Jin Takeuchi, Taiichi Kyo, K. Naito, H. Sao, Masatomo Takahashi, S. Miyawaki, Kazutaka Kuriyama, S. Ohtake, F. Yagasaki, Hirokazu Murakami, N. Asou, Teruo Ino, T. Okamoto, Noriko Usui, M. Nishimura, K. Shinagawa, T. Fukushima, Hirokuni Taguchi, T. Morii, Shuichi Mizuta, Hideki Akiyama, Y. Nakamura, T. Ohshima, Ryuzo Ohno (2002)Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study
M. Wetzler, R. Dodge, K. Mrózek, A. Carroll, R. Tantravahi, A. Block, M. Pettenati, M. Beau, S. Frankel, Carleton Stewart, T. Szatrowski, C. Schiffer, R. Larson, C. Bloomfield (1999)Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.
Blood, 93 11
In the pre-imatinib era, the treatment outcome of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) was dismal. Complete remission was generally achieved only in about 50% to 60% of patients, and allogeneic hematopoietic stem cell transplantation (allo-HSCT), when feasible in younger patients, was virtually the sole curative modality. Imatinib has changed the situation dramatically, however, in combination with conventional chemotherapy or with corticosteroid alone, producing about 95% complete remission and thus increasing the number of patients undergoing allo-HSCT. Currently, the overall survival of patients who have undergone allo-HSCT exceeds 50%, and a considerable proportion of patients for whom allo-HSCT is not feasible are predictably curable. The next question is how to prevent relapse, which is observed not only in more than half of patients for whom allo-HSCT is not feasible but also in a considerable number of patients after allo-HSCT. Thus, improvement of postremission therapy is crucial. Whether intensive chemotherapy with currently available cytotoxic drugs contributes to the prevention of relapse is questionable, because intensive chemotherapy alone in the pre-imatinib era nearly always failed to cure this disease. Promising partners to be combined with imatinib or with a second-generation tyrosine kinase inhibitor (TKI) will be corticosteroids and vincristine. New TKIs such as dasatinib should be incorporated into the early phase of postremission therapy. Recognizing the small number of patients with Ph+ ALL, intergroup or international studies are necessary to develop the best postremission therapy. In the near future, it is hoped that Ph+ ALL will become one of the leukemias for which allo-HSCT is offered only for relapsed or extremely high-risk patients.
Current Hematologic Malignancy Reports – Springer Journals
Published: Jul 22, 2010
Access the full text.
Sign up today, get DeepDyve free for 14 days.